DE69733611D1 - Verfahren und potenzierte zusammensetzung zur behandlung von migräne - Google Patents
Verfahren und potenzierte zusammensetzung zur behandlung von migräneInfo
- Publication number
- DE69733611D1 DE69733611D1 DE69733611T DE69733611T DE69733611D1 DE 69733611 D1 DE69733611 D1 DE 69733611D1 DE 69733611 T DE69733611 T DE 69733611T DE 69733611 T DE69733611 T DE 69733611T DE 69733611 D1 DE69733611 D1 DE 69733611D1
- Authority
- DE
- Germany
- Prior art keywords
- treating migraine
- potential composition
- migraine
- potential
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72792396A | 1996-10-09 | 1996-10-09 | |
US727923 | 1996-10-09 | ||
US08/736,370 US5891885A (en) | 1996-10-09 | 1996-10-24 | Method for treating migraine |
US736370 | 1996-10-24 | ||
PCT/US1997/017828 WO1998015275A2 (en) | 1996-10-09 | 1997-10-06 | Method and potentiated composition for treating migraine |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69733611D1 true DE69733611D1 (de) | 2005-07-28 |
DE69733611T2 DE69733611T2 (de) | 2006-05-04 |
Family
ID=27111608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69733611T Expired - Lifetime DE69733611T2 (de) | 1996-10-09 | 1997-10-06 | Verfahren und potenzierte zusammensetzung zur behandlung von migräne |
Country Status (9)
Country | Link |
---|---|
US (3) | US5891885A (de) |
EP (1) | EP0932416B1 (de) |
JP (1) | JP2000508341A (de) |
AT (1) | ATE298250T1 (de) |
AU (1) | AU4806197A (de) |
CA (1) | CA2267893C (de) |
DE (1) | DE69733611T2 (de) |
ES (1) | ES2244992T3 (de) |
WO (1) | WO1998015275A2 (de) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6413961B1 (en) * | 1995-12-12 | 2002-07-02 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
GB9710767D0 (en) * | 1996-06-26 | 1997-07-23 | On Ninh | Analgesic and anti-inflamatory compositions comprising domperidone and methods of using same |
US6586458B1 (en) | 1996-08-16 | 2003-07-01 | Pozen Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
US8022095B2 (en) | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
EE200000050A (et) * | 1997-07-21 | 2000-10-16 | H. Levin Bruce | Ravimkoostised, kasutusvalmis komplektid ja meetodid peaaju neurovaskulaarsete häirete ja lihaspingepeavalu inhibeerimiseks |
US7799337B2 (en) | 1997-07-21 | 2010-09-21 | Levin Bruce H | Method for directed intranasal administration of a composition |
US6432986B2 (en) | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
ATE344035T1 (de) * | 1998-07-16 | 2006-11-15 | Memorial Sloan Kettering Inst | Topische zusammensetzung enthaltend ein opioid- analgetikum und einen nmda-antagonisten |
GB9816899D0 (en) | 1998-08-05 | 1998-09-30 | Boots Co Plc | Therapeutic agents |
DE69922688T2 (de) | 1998-11-02 | 2005-12-01 | Merck & Co. Inc. | Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne |
US7163705B2 (en) * | 1998-12-15 | 2007-01-16 | Wm. Wrigley Jr. Company | Coated chewing gum product and method of making |
AU3596500A (en) * | 1999-02-19 | 2000-09-04 | Pozen, Inc. | Formulation of 5-ht agonists with cox-2 inhibitors |
IL136023A0 (en) * | 1999-05-14 | 2001-05-20 | Pfizer Prod Inc | 5ht1 receptor agonists and either a cox-2 inhibitor or nsaid for the treatment of migraine |
JP2001064205A (ja) * | 1999-06-25 | 2001-03-13 | Dai Ichi Seiyaku Co Ltd | 製剤組成物 |
CO5190678A1 (es) * | 1999-06-30 | 2002-08-29 | Pfizer Prod Inc | Terapia combinada para el tratamiento de la migrana |
IL136961A0 (en) * | 1999-06-30 | 2001-06-14 | Pfizer Prod Inc | 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine |
CO5190664A1 (es) * | 1999-06-30 | 2002-08-29 | Pfizer Prod Inc | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 |
ES2275525T3 (es) | 1999-07-12 | 2007-06-16 | Capnia Incorporated | Aparato para aliviar dolores de cabeza, rinitis y otras afecciones comunes. |
US6959708B1 (en) * | 1999-11-08 | 2005-11-01 | Capnia, Incorporated | Method for co-application of gases and drugs to potentiate their action in relieving headaches, angina and other ailments |
US20070039615A1 (en) * | 1999-11-08 | 2007-02-22 | Capnia, Incorporated | Methods and apparatus for treating rhinitis |
US20060172017A1 (en) | 1999-11-08 | 2006-08-03 | Capnia, Incorporated | Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces |
US6492334B1 (en) | 1999-12-30 | 2002-12-10 | Robert James Generale | Tri-compound analgesic for treating inflammation and pain |
DE10035865C2 (de) * | 2000-07-24 | 2003-02-06 | Norbert Over | Verwendung von wässrigen Spraylösungen des lokalanästhetischen Mittels Lidocain zur prophylaktischen Behandlung von Migräne |
FR2815873B1 (fr) * | 2000-09-29 | 2002-12-06 | Adir | Composition pharmaceutique pour l'administration transmucosale d'une association dihydroergotamine/ metoclopramide |
US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
GB0104554D0 (en) * | 2001-02-23 | 2001-04-11 | Glaxo Group Ltd | New uses |
DK1395289T3 (da) * | 2001-06-07 | 2011-03-28 | Christine Dr Sang | Behandling af neuropatisk smerte med en N-methyl-D-aspartat- (NMDA-)receptorantagonist |
US6685951B2 (en) | 2001-07-05 | 2004-02-03 | R. T. Alamo Ventures I, Inc. | Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine |
US20030008005A1 (en) * | 2001-07-05 | 2003-01-09 | R.T. Alamo Ventures, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
US20030017175A1 (en) * | 2001-07-05 | 2003-01-23 | R.T. Alamo Ventures I, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
US20030022910A1 (en) * | 2001-07-05 | 2003-01-30 | R.T. Alamo Ventures I, Inc. | Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine |
US20030198669A1 (en) * | 2001-07-05 | 2003-10-23 | R.T. Alamo Ventures I, Llc | Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine |
EP1414424A1 (de) * | 2001-07-31 | 2004-05-06 | Lothar Saiger | Mittel zur behandlung der symptome von demenzerkrankungen enthaltend ein zusätzliches lokalanästhetikum |
KR20050042210A (ko) * | 2001-11-02 | 2005-05-06 | 메리디안 메디칼 테크놀로지즈 인코포레이티드 | 약제 콘테이너, 약물 투여용 약제 분배 키트 및 그것을패키징하는 방법 |
RU2004126093A (ru) * | 2002-02-26 | 2005-04-10 | Орто-Макнейл Фармасьютикал, Инк. (Us) | Комбинированная терапия для лечения мигрени, включающая применение производных противосудорожных средств и средств от мигрени |
US20030196929A1 (en) * | 2002-04-19 | 2003-10-23 | Govindan Gopinathan | Pharmaceutical kit for migraine headache treatment |
US20050209654A1 (en) * | 2002-05-09 | 2005-09-22 | Boveja Birinder R | Method and system for providing adjunct (add-on) therapy for depression, anxiety and obsessive-compulsive disorders by providing electrical pulses to vagus nerve(s) |
US20060193788A1 (en) * | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
US6932988B2 (en) | 2002-09-16 | 2005-08-23 | Suzanne Cruse | Kit and method for migraine headache treatment |
AU2003295823B2 (en) * | 2002-11-26 | 2009-11-05 | Alexza Pharmaceuticals, Inc. | Treatment of headache with antipsychotics delivered by inhalation |
WO2004047844A1 (en) * | 2002-11-26 | 2004-06-10 | Alexza Pharmaceuticals, Inc. | Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain |
CA2509023C (en) | 2002-12-26 | 2011-05-24 | Pozen Inc. | Multilayer dosage forms containing nsaids and triptans |
US20050031652A1 (en) * | 2003-02-25 | 2005-02-10 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
US20050147584A1 (en) * | 2004-01-05 | 2005-07-07 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
WO2004112723A2 (en) * | 2003-06-20 | 2004-12-29 | Ronald Aung-Din | Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
CA2538237A1 (en) * | 2003-09-10 | 2005-03-24 | Map Pharmaceuticals, Inc. | Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
KR20060124731A (ko) * | 2004-01-29 | 2006-12-05 | 뉴로몰레큘라 파마슈티칼스, 인코포레이티드 | 중추신경계-관련 질환 치료용 nmda 수용체 길항제 및mao-억제제 또는 gadph-억제제의 배합물 |
DE102004040630A1 (de) * | 2004-08-21 | 2006-03-09 | Balaban, Romulus, Dr.med. | Kombinationstherapie mit Procain |
EP1789028A2 (de) * | 2004-08-24 | 2007-05-30 | Neuromolecular Pharmaceuticals Inc | Zusammensetzungen zur behandlung von nociceptiven schmerzen |
EP1799264A2 (de) * | 2004-10-08 | 2007-06-27 | Neuromolecular Pharmaceuticals Inc | Verfahren und zusammensetzungen zur behandlung von migräne |
DE05852057T1 (de) | 2004-11-23 | 2007-11-29 | Neuromolecular Pharmaceuticals Inc., Emeryville | Zusammensetzung aus einer beschichtung oder matrix mit verzögerter freisetzung und einem nmda-rezeptorantagonisten sowie verfahren zur verabreichung eines solchen nmda-rezeptorantagonisten an ein subjekt |
US7619007B2 (en) * | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
CA2588296A1 (en) * | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
CA2604052C (en) | 2005-04-06 | 2014-07-08 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of cns-related conditions |
EP1728520A1 (de) * | 2005-05-04 | 2006-12-06 | Charité - Universitätsmedizin Berlin | Verwendung von spezifisch an das Serotonin-Transport-Protein (SERT) bindenden Radiopharmaka zur Herstellung eines Diagnostikums zur Untersuchung von Kopfschmerzerkrankungen |
WO2006117218A2 (en) * | 2005-05-04 | 2006-11-09 | Charite Universitätsmedizin - Berlin | Serotonin-transport-protein binding radiopharmaceutical for the production of a diagnostic medicament for the diagnosis of headache |
TW200800959A (en) | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
US7834007B2 (en) * | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
WO2007146073A2 (en) * | 2006-06-09 | 2007-12-21 | Wyeth | Method for enhancing cognitive function |
US7767206B2 (en) * | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
PL2124556T3 (pl) | 2006-10-09 | 2015-02-27 | Charleston Laboratories Inc | Kompozycje farmaceutyczne |
US20080139510A1 (en) * | 2006-12-07 | 2008-06-12 | Abe Rose | Treatment of migraine headaches with sublingual amino acids |
EP2425820B1 (de) | 2007-02-11 | 2015-04-08 | MAP Pharmaceuticals Inc | Verfahren zur therapeutischen Verabreichung von DHE zur schnellen Linderung von Migräne bei gleichzeitiger Minimierung von Nebenwirkungsprofilen |
WO2009089494A2 (en) | 2008-01-09 | 2009-07-16 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
US20110082150A1 (en) * | 2008-02-11 | 2011-04-07 | Robert Owen Cook | Headache pre-emption by dihydroergotamine treatment during headache Precursor events |
WO2009103150A1 (en) * | 2008-02-20 | 2009-08-27 | Kevin David Smith | Method for treating migraine headaches |
WO2010009063A2 (en) * | 2008-07-15 | 2010-01-21 | Basf Corporation | Non-cytotoxic chlorine dioxide fluids |
DE102008037682A1 (de) * | 2008-08-14 | 2010-04-08 | Strackharn, Klaus, Dr.med. | Verwendung äquipotenter Dosierungen von Lokalanästetika oder Derivaten davon zur Therapie chronischer Schmerzen |
US20110171141A1 (en) * | 2009-06-26 | 2011-07-14 | Kellerman Donald J | Administration of dihydroergotamine mesylate particles using a metered dose inhaler |
EP2451274B1 (de) | 2009-07-08 | 2017-10-04 | Charleston Laboratories, Inc. | Pharmazeutische zusammensetzungen |
JP5885668B2 (ja) | 2009-12-02 | 2016-03-15 | アダマス ファーマシューティカルズ, インコーポレイテッド | アマンタジン組成物および使用方法 |
WO2011127235A1 (en) | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
EP2903604A1 (de) * | 2012-09-28 | 2015-08-12 | St. Renatus, LLC | Pharmazeutische zusammensetzung mit benzylalkohol zur behandlung von migräne |
US9050330B2 (en) * | 2012-12-06 | 2015-06-09 | Jose C. Ramon-de-Jesus | Method, composition and kit for treating frequent headaches |
WO2014100351A2 (en) | 2012-12-21 | 2014-06-26 | Map Pharmaceuticals, Inc. | 8'-hydroxy-dihydroergotamine compounds and compositions |
WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
US20150290174A1 (en) * | 2014-04-11 | 2015-10-15 | Resuscitate MOE LLC | Pharmaceutical formulations and method of using the same for alleviating symptoms of hangover, stomach flu or migraine |
US10179109B2 (en) | 2016-03-04 | 2019-01-15 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates |
US11103499B2 (en) | 2016-08-26 | 2021-08-31 | EXCIVA (UG) (haftungsbeschränkt) | Compositions and methods thereof |
CN110831584B (zh) * | 2017-05-04 | 2023-03-10 | 埃克塞瓦有限责任公司 | 具有新颖的组合物、组合的靶向药物拯救及其方法 |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
EP3955918A1 (de) | 2019-04-17 | 2022-02-23 | COMPASS Pathfinder Limited | Verfahren zur behandlung neurokognitiver störungen, chronischer schmerzen und verringerung von entzündung |
AU2021265602A1 (en) | 2020-05-01 | 2023-01-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | E protein channel blockers and ORF3 inhibitors as anti-covid-19 agents |
WO2022113069A1 (en) | 2020-11-24 | 2022-06-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | E protein channel blockers and orf3 inhibitors as anti-covid-19 agents |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1584464A (en) * | 1977-04-19 | 1981-02-11 | Farmaceutici Italia | Ergot alkaloids |
AU548467B2 (en) * | 1980-08-12 | 1985-12-12 | Glaxo Group Limited | Tryptamines and their isoindolylethyl derivatives |
US5021428A (en) * | 1985-07-02 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds for the prophylactic treatment of migraine |
US5200413A (en) * | 1987-01-05 | 1993-04-06 | Beecham Group P.L.C. | Indolyl carboxamides useful treating migraine, cluster headache, trigeminal neuralgia or emesis |
US5364863A (en) * | 1987-09-08 | 1994-11-15 | Eli Lilly And Company | Specific 5-HT3 antagonists |
DE3823378A1 (de) * | 1988-07-09 | 1990-01-11 | Knoll Ag | (s)-emopamil zur anwendung bei der behandlung von migraene |
AT392967B (de) * | 1989-01-24 | 1991-07-25 | Laevosan Gmbh & Co Kg | Neue 1-(3-(2-hydroxy-3-alkylaminopropoxy)-2- thienyl)-3-phenyl-1-propanone und verfahren zu deren herstellung |
US4916125A (en) * | 1989-07-11 | 1990-04-10 | Sandoz Ltd. | Method of treating migraine |
US5155218A (en) * | 1990-05-08 | 1992-10-13 | Neurogenetic Corporation | Dna encoding human 5-ht1d receptors |
JP3122671B2 (ja) * | 1990-05-23 | 2001-01-09 | 協和醗酵工業株式会社 | 複素環式化合物 |
YU48855B (sh) * | 1990-06-07 | 2002-06-19 | The Wellcome Foundation Limited | Heterociklična jedinjenja i njihovi derivati koji su modifikatori dejstva 5-hidroksi-triptamina i postupak njihovog dobijanja |
CA2020018A1 (en) * | 1990-06-27 | 1991-12-28 | Don L. Simmons | Method and composition for treating the migraine complex |
EP0754450A1 (de) * | 1990-10-16 | 1997-01-22 | Mayor Pharmaceuticals Laboratories,Inc. | Vitamin-Mineral-Behandlungsverfahren und Zusammensetzungen |
US5317103A (en) * | 1991-01-15 | 1994-05-31 | Merck Sharp & Dohme Limited | Indole-substituted five-membered heteroaromatic compounds as 5-HT1 agonists |
US5491148A (en) * | 1991-04-26 | 1996-02-13 | Syntex (U.S.A.) Inc. | Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists |
GB9113802D0 (en) * | 1991-06-26 | 1991-08-14 | Smithkline Beecham Plc | Medicaments |
CA2084531A1 (en) * | 1991-12-19 | 1993-06-20 | David W. Smith | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines |
GB9221761D0 (en) * | 1992-10-16 | 1992-12-02 | Glaxo Group Ltd | Chemical compounds |
US5242949A (en) * | 1992-03-13 | 1993-09-07 | Rugby-Darby Group Companies, Inc. | Treating classic migraine |
US5436255A (en) * | 1992-07-23 | 1995-07-25 | Pfizer Inc. | Method of treating diseases susceptable to treatment by blocking NMDA-receptors |
DE4229805A1 (de) * | 1992-09-07 | 1994-03-24 | Werner E G Prof Dr Mueller | Kalzium-Kanal-Antagonisten oder deren Derivate zur Herstellung eines Arzneimittels zur Bekämpfung von Erkrankungen, die durch Prion-Proteine oder Prion-analoge Proteine ausgelöst werden |
CA2146637C (en) * | 1992-10-09 | 2001-02-13 | James Grigg Upson | Pharmaceutical compositions and methods for treating cold symptoms |
US5922773A (en) * | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
DK154092D0 (da) * | 1992-12-23 | 1992-12-23 | Neurosearch As | Imidazolforbindelser, deres fremstilling og anvendelse |
CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
WO1995006468A1 (en) * | 1993-09-01 | 1995-03-09 | Smithkline Beecham Corporation | Method for treating migraine headaches |
GB9321812D0 (en) * | 1993-10-22 | 1993-12-15 | Smithkline Beecham Plc | Pharmaceuticals |
US5468768A (en) * | 1994-01-06 | 1995-11-21 | Bristol-Myers Squibb Company | Antimigraine derivatives of indolylcycloalkanylamines |
GB9411045D0 (en) * | 1994-06-02 | 1994-07-20 | Smithkline Beecham Plc | Compounds and use |
US5597809A (en) * | 1994-06-23 | 1997-01-28 | Massachusetts Eye & Ear Infirmary | Treatment of optic neuritis |
ES2214532T3 (es) * | 1995-03-03 | 2004-09-16 | Endo Pharmaceuticals Inc. | Uso de dextrorfano o dextrometorfano para el tratamiento de la incontinencia urinaria. |
-
1996
- 1996-10-24 US US08/736,370 patent/US5891885A/en not_active Expired - Lifetime
-
1997
- 1997-05-19 US US08/858,269 patent/US5939425A/en not_active Expired - Lifetime
- 1997-10-06 JP JP10517619A patent/JP2000508341A/ja active Pending
- 1997-10-06 EP EP97910772A patent/EP0932416B1/de not_active Expired - Lifetime
- 1997-10-06 AT AT97910772T patent/ATE298250T1/de not_active IP Right Cessation
- 1997-10-06 ES ES97910772T patent/ES2244992T3/es not_active Expired - Lifetime
- 1997-10-06 DE DE69733611T patent/DE69733611T2/de not_active Expired - Lifetime
- 1997-10-06 AU AU48061/97A patent/AU4806197A/en not_active Abandoned
- 1997-10-06 WO PCT/US1997/017828 patent/WO1998015275A2/en active IP Right Grant
- 1997-10-06 CA CA2267893A patent/CA2267893C/en not_active Expired - Fee Related
-
1999
- 1999-01-07 US US09/226,297 patent/US6043244A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU4806197A (en) | 1998-05-05 |
EP0932416A2 (de) | 1999-08-04 |
EP0932416B1 (de) | 2005-06-22 |
CA2267893A1 (en) | 1998-04-16 |
ES2244992T3 (es) | 2005-12-16 |
DE69733611T2 (de) | 2006-05-04 |
ATE298250T1 (de) | 2005-07-15 |
CA2267893C (en) | 2010-12-14 |
WO1998015275A2 (en) | 1998-04-16 |
WO1998015275A3 (en) | 1998-08-06 |
US5939425A (en) | 1999-08-17 |
US6043244A (en) | 2000-03-28 |
US5891885A (en) | 1999-04-06 |
JP2000508341A (ja) | 2000-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69733611D1 (de) | Verfahren und potenzierte zusammensetzung zur behandlung von migräne | |
ATE221781T1 (de) | Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms | |
DE60043308D1 (de) | Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin | |
DE69733132D1 (de) | Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen | |
DE69942680D1 (de) | Verfahren und Zusammensetzungen zur Prävention und Behandlung von Anämie | |
DE69611251T2 (de) | Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges | |
DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
DE60039783D1 (de) | Lfa-1 antagonisten und tnf-alpha antagonisten zur | |
DE69833971D1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
ATE209490T1 (de) | Substanz p antagonisten zur behandlung von erbrechen | |
ATE135690T1 (de) | Substituierte tetrahydropyridine und hydroxypiperidine als mittel zur behandlung des zentralen nervensystems | |
WO2001001972A3 (en) | SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | |
DE69026881D1 (de) | 4-Substituiertes 17-beta-(Cyclopropyl-amino)-androst-5-en-3-beta-ol und seine Derivate, verwendbar als Inhibitoren der C17-20-Lyase | |
DE69921130D1 (de) | Verfahren und stoffe zur behandlung des prostatakarzinomes | |
MXPA01003501A (es) | Metodo para moderar el estres o tension de las plantas. | |
DE69905616T2 (de) | Verfahren und zusammensetzung zur behandlung und vorbeugung von mycobacterium infektionen | |
DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
DE69626311D1 (de) | Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür | |
DE69429856D1 (de) | Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit | |
ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
DE69922364D1 (de) | Verfahren zur immunisierung und behandlung von h. pylori infektion | |
DE60013326D1 (de) | Verbindungen und verfahren zur behandlung von schmerz | |
ATE251462T1 (de) | Verfahren zur behandlung von narbengewebe | |
DE60218203D1 (de) | Verbindungen und verfahren zur behandlung einer hyperaktiven blase | |
UA48962C2 (uk) | Біциклічні антагоністи тахікінінів, фармацевтична композиція та спосіб лікування |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: ENDO PHARMACEUTICALS INC. (N.D.GES.D. STAATES DELA |
|
8364 | No opposition during term of opposition |